Suppression of insulin signaling can disrupt the phosphatidylinositol-3-kinase pathway, which promotes the reduced synthesis of proteins, impairing muscle function and integrity and contributing to the development of sarcopenia. The gene discussed is INS; the disease is sarcopenia.